Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO and BASEL, Switzerland, Apr. 9 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the [...]